Compass Pathways has a Cash Ratio of 13.55. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Compass Pathways's Cash Ratio or its related term are showing as below:
CMPS'
s Cash Ratio Range Over the Past 10 Years
Min: 1.05 Med: 14.61 Max: 40.55
Current: 13.55
During the past 6 years, Compass Pathways's highest Cash Ratio was 40.55. The lowest was 1.05. And the median was 14.61.
CMPS's Cash Ratio is ranked better than 97.87% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 0.5
vs CMPS: 13.55
Compass Pathways Cash Ratio Historical Data
The historical data trend for Compass Pathways's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Compass Pathways's Cash Ratio
For the Medical Care Facilities subindustry, Compass Pathways's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Compass Pathways's Cash Ratio Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Compass Pathways's Cash Ratio falls into.
Compass Pathways Cash Ratio Calculation
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Compass Pathways's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Compass Pathways (NAS:CMPS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Compass Pathways Cash Ratio Related Terms
Thank you for viewing the detailed overview of Compass Pathways's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Compass Pathways (Compass Pathways) Business Description
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMPS has been successfully added to your 